X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
The results from the Phase 2 GUARD trial of Angion’s ANG-3777 in patients undergoing cardiac surgery involving cardiopulmonary bypass at risk for developing acute kidney injury.
Lead Product(s): Terevalefim
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: ANG-3777
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: CSL Vifor
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 09, 2021
Details:
ANG-3777 is a small molecule designed to mimic the biological activity of hepatocyte growth factor (HGF), trial did not meet its primary endpoint of percentage increase in serum creatinine based upon the area under the curve (AUC).
Lead Product(s): Terevalefim
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: ANG-3777
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 09, 2021
Details:
The overall safety profile of ANG-3777 in this trial was consistent with the overall experience in its clinical development program and consistent with the published literature in this patient population.
Lead Product(s): Terevalefim
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: ANG-3777
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: CSL Vifor
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 26, 2021
Details:
Under the terms of the agreement, Vifor Pharma will receive an exclusive global license, excluding China, Taiwan, Hong Kong and Macau, for all ANG-3777 nephrology indications.
Lead Product(s): Terevalefim
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: ANG-3777
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: CSL Vifor
Deal Size: $30.0 million Upfront Cash: $30.0 million
Deal Type: Licensing Agreement November 09, 2020
Details:
The Phase 2 trial is a multicenter, prospective, randomized, double-blind, placebo-controlled trial to assess safety and efficacy of ANG-3777 in patients hospitalized with confirmed COVID-19 pneumonia.
Lead Product(s): Terevalefim
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: ANG-3777
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 08, 2020
Details:
The Company is going to discuss the effect of ANG-3777 on Hepatocyte Growth Factor Receptor c-MET Signaling.
Lead Product(s): Terevalefim
Therapeutic Area: Nephrology Product Name: ANG-3777
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: CSL Vifor
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 29, 2020
Details:
The publication details the results of the administration of ANG-3777 in patients who have undergone deceased-donor kidney transplantation and had signs of kidney injury.
Lead Product(s): Terevalefim
Therapeutic Area: Nephrology Product Name: ANG-3777
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: CSL Vifor
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 05, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
